MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Condition(s) studied

Investigational drug(s) / intervention(s)

MammaPrint, BluePrint, and Full-Genome Testing: Agendia will run MammaPrint and BluePrint tests using the full genome testing array.

Study summary

The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.

Eligibility

Primary outcome measure(s)

• A large scale registry of full genome expression data to investigate new gene associations with prognostic and/or predictive value will be created. — 10 years
  Create a large scale registry of full genome expression data with clinical data to investigate possible new gene associations with prognostic or predictive value.
• A shared registry infrastructure to examine smaller groups of interest. — 10 years
  Create a shared registry infrastructure to examine smaller groups of interest.

Trial sites (134)

+ 94 more sites — see the full list on the official registry below.

Other trials for the same condition